{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:06:42Z","timestamp":1784038002225,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["Z230021"],"award-info":[{"award-number":["Z230021"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02109-z","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:33:48Z","timestamp":1774434828000},"page":"1326-1338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Eosinophilia-related adverse events reporting associated with medications: a disproportionality and regression analysis of the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"48","author":[{"given":"Haimo","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"1","key":"2109_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajh.26352","volume":"97","author":"W Shomali","year":"2022","unstructured":"Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(1):129\u201348. https:\/\/doi.org\/10.1002\/ajh.26352.","journal-title":"Am J Hematol"},{"issue":"1","key":"2109_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/all.15544","volume":"78","author":"P Valent","year":"2023","unstructured":"Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023;78(1):47\u201359. https:\/\/doi.org\/10.1111\/all.15544.","journal-title":"Allergy"},{"issue":"2","key":"2109_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jaip.2018.08.013","volume":"7","author":"AR Wolfson","year":"2019","unstructured":"Wolfson AR, Zhou L, Li Y, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module. J Allergy Clin Immunol Pract. 2019;7(2):633\u201340. https:\/\/doi.org\/10.1016\/j.jaip.2018.08.013.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"2109_CR4","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1111\/bjd.15461","volume":"177","author":"Y Teo","year":"2017","unstructured":"Teo Y, Walsh S, Creamer D. Cutaneous adverse drug reaction referrals to a liaison dermatology service. Br J Dermatol. 2017;177(4):e141\u20132. https:\/\/doi.org\/10.1111\/bjd.15461.","journal-title":"Br J Dermatol"},{"issue":"5","key":"2109_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071\u201380. https:\/\/doi.org\/10.1111\/bjd.12501.","journal-title":"Br J Dermatol"},{"issue":"10106","key":"2109_CR6","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","volume":"390","author":"TA Duong","year":"2017","unstructured":"Duong TA, Valeyrie-Allanore L, Wolkenstein P, et al. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996\u20132011. https:\/\/doi.org\/10.1016\/S0140-6736(16)30378-6.","journal-title":"Lancet"},{"issue":"4","key":"2109_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009688","volume":"97","author":"C Bartal","year":"2018","unstructured":"Bartal C, Sagy I, Barski L. Drug-induced eosinophilic pneumonia: a review of 196 case reports. Medicine (Baltimore). 2018;97(4):e9688. https:\/\/doi.org\/10.1097\/MD.0000000000009688.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2109_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-024-04866-9","volume":"18","author":"K Hafidh","year":"2024","unstructured":"Hafidh K, Kazmi T, Alhaj A, et al. Carbimazole-induced eosinophilic gastroenteritis in a young female with abdominal pain and ascites: a case report. J Med Case Rep. 2024;18(1):559. https:\/\/doi.org\/10.1186\/s13256-024-04866-9.","journal-title":"J Med Case Rep"},{"issue":"1","key":"2109_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-025-01914-x","volume":"45","author":"J Wu","year":"2025","unstructured":"Wu J, Li L, Ten W, et al. Dupilumab-induced eosinophilic granulomatosis with polyangiitis complicated by peripheral neuropathic pain: a case report and literature review. J Clin Immunol. 2025;45(1):114. https:\/\/doi.org\/10.1007\/s10875-025-01914-x.","journal-title":"J Clin Immunol"},{"issue":"5","key":"2109_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.615","volume":"10","author":"EM Rodriguez","year":"2001","unstructured":"Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10(5):407\u201310. https:\/\/doi.org\/10.1002\/pds.615.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2109_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03171-9","volume":"24","author":"P Chen","year":"2023","unstructured":"Chen P, Zhu J, Xu Y, et al. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database. BMC Nephrol. 2023;24(1):107. https:\/\/doi.org\/10.1186\/s12882-023-03171-9.","journal-title":"BMC Nephrol"},{"key":"2109_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490334","volume":"15","author":"C Liang","year":"2024","unstructured":"Liang C, An P, Zhang Y, et al. Fatal outcome related to drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis of FAERS database and a systematic review of cases. Front Immunol. 2024;15:1490334. https:\/\/doi.org\/10.3389\/fimmu.2024.1490334.","journal-title":"Front Immunol"},{"key":"2109_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8525789","volume":"2017","author":"M Rachid","year":"2017","unstructured":"Rachid M, Ahmad K, Saunders-Kurban M, et al. Daptomycin-induced acute eosinophilic pneumonia: late onset and quick recovery. Case Rep Pulmonol. 2017;2017:8525789. https:\/\/doi.org\/10.1155\/2017\/8525789.","journal-title":"Case Rep Pulmonol"},{"key":"2109_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.seizure.2025.01.002","volume":"125","author":"J Qian","year":"2025","unstructured":"Qian J, Xue X, Ezeja L, et al. Post-marketing safety of antiseizure medications: focus on serious adverse effects including drug reaction with eosinophilia and systemic symptoms (DRESS). Seizure. 2025;125:37\u201343. https:\/\/doi.org\/10.1016\/j.seizure.2025.01.002.","journal-title":"Seizure"},{"issue":"3","key":"2109_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/14737167.2023.2282668","volume":"24","author":"A Ali","year":"2024","unstructured":"Ali A, Garc\u00eda E, Torres-Duque CA, et al. Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia. Expert Rev Pharmacoecon Outcomes Res. 2024;24(3):361\u201374. https:\/\/doi.org\/10.1080\/14737167.2023.2282668.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"49","key":"2109_CR16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2411919121","volume":"121","author":"EY Klein","year":"2024","unstructured":"Klein EY, Impalli I, Poleon S, et al. Global trends in antibiotic consumption during 2016-2023 and future projections through 2030. Proc Natl Acad Sci USA. 2024;121(49):e2411919121. https:\/\/doi.org\/10.1073\/pnas.2411919121.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2109_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.18176\/jiaci.0823","volume":"32","author":"JM Olaguibel","year":"2022","unstructured":"Olaguibel JM, Sastre J, Rodr\u00edguez JM, et al. Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes. J Investig Allergol Clin Immunol. 2022;32(3):165\u201380. https:\/\/doi.org\/10.18176\/jiaci.0823.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2109_CR18","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2147\/JIR.S357758","volume":"15","author":"J Xue","year":"2022","unstructured":"Xue J, Jiang J, Liu Y. The neutrophil\/lymphocyte ratio is an independent predictor of all-cause mortality in patients with idiopathic hypereosinophilic syndrome. J Inflamm Res. 2022;15:1899\u2013906. https:\/\/doi.org\/10.2147\/JIR.S357758.","journal-title":"J Inflamm Res"},{"issue":"3","key":"2109_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00134-022-06967-9","volume":"49","author":"A Gaillet","year":"2023","unstructured":"Gaillet A, Bay P, P\u00e9ju E, et al. Epidemiology, clinical presentation, and outcomes of 620 patients with eosinophilia in the intensive care unit. Intensive Care Med. 2023;49(3):291\u2013301. https:\/\/doi.org\/10.1007\/s00134-022-06967-9.","journal-title":"Intensive Care Med"},{"key":"2109_CR20","doi-asserted-by":"publisher","unstructured":"Mukherjee EM, Park D, Krantz MS, et al. Demographics, overlap, and latency of severe cutaneous adverse reactions in an FDA database. Preprint.\u00a0medRxiv. 2025;2025.03.05.25323441; https:\/\/doi.org\/10.1101\/2025.03.05.25323441","DOI":"10.1101\/2025.03.05.25323441"},{"issue":"11","key":"2109_CR21","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1432-2277.2009.00927.x","volume":"22","author":"D Weiskopf","year":"2009","unstructured":"Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int. 2009;22(11):1041\u201350. https:\/\/doi.org\/10.1111\/j.1432-2277.2009.00927.x.","journal-title":"Transpl Int"},{"key":"2109_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/00185787251341739","author":"SKA Bhumireddy","year":"2025","unstructured":"Bhumireddy SKA, Gudla SS, Vadaga AK, et al. Vancomycin-induced DRESS syndrome: a systematic review of case reports. Hosp Pharm. 2025. https:\/\/doi.org\/10.1177\/00185787251341739.","journal-title":"Hosp Pharm"},{"issue":"4","key":"2109_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3945\/ajcn.113.068122","volume":"99","author":"JE Winter","year":"2014","unstructured":"Winter JE, MacInnis RJ, Wattanapenpaiboon N, et al. BMI and all-cause mortality in older adults: a meta-analysis. Am J Clin Nutr. 2014;99(4):875\u201390. https:\/\/doi.org\/10.3945\/ajcn.113.068122.","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"2109_CR24","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s15010-024-02349-z","volume":"52","author":"A Gidari","year":"2024","unstructured":"Gidari A, Pallotto C, Francisci D. Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series. Infection. 2024;52(6):2145\u201368. https:\/\/doi.org\/10.1007\/s15010-024-02349-z.","journal-title":"Infection"},{"key":"2109_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.seizure.2017.10.018","volume":"53","author":"K Ksouda","year":"2017","unstructured":"Ksouda K, Affes H, Mahfoudh N, et al. HLA-A*31:01 and carbamazepine-induced DRESS syndrom in a sample of North African population. Seizure. 2017;53:42\u20136. https:\/\/doi.org\/10.1016\/j.seizure.2017.10.018.","journal-title":"Seizure"},{"issue":"5","key":"2109_CR26","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","volume":"20","author":"T Ozeki","year":"2011","unstructured":"Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034\u201341. https:\/\/doi.org\/10.1093\/hmg\/ddq537.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"2109_CR27","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","volume":"364","author":"M McCormack","year":"2011","unstructured":"McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1013297.","journal-title":"N Engl J Med"},{"key":"2109_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.867490","volume":"13","author":"K Tiwattanon","year":"2022","unstructured":"Tiwattanon K, John S, Koomdee N, et al. Implementation of HLA-B*15:02 genotyping as standard-of-care for reducing carbamazepine\/oxcarbazepine induced cutaneous adverse drug reactions in Thailand. Front Pharmacol. 2022;13:867490. https:\/\/doi.org\/10.3389\/fphar.2022.867490.","journal-title":"Front Pharmacol"},{"key":"2109_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106321","volume":"162","author":"W Manuyakorn","year":"2020","unstructured":"Manuyakorn W, Likkasittipan P, Wattanapokayakit S, et al. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children. Epilepsy Res. 2020;162:106321. https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106321.","journal-title":"Epilepsy Res"},{"issue":"5","key":"2109_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/pds.4979","volume":"29","author":"C Sukasem","year":"2020","unstructured":"Sukasem C, Sririttha S, Tempark T, et al. Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population. Pharmacoepidemiol Drug Saf. 2020;29(5):565\u201374. https:\/\/doi.org\/10.1002\/pds.4979.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"2109_CR31","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/epi.13509","volume":"57","author":"W Manuyakorn","year":"2016","unstructured":"Manuyakorn W, Mahasirimongkol S, Likkasittipan P, et al. Association of HLA genotypes with phenobarbital hypersensitivity in children. Epilepsia. 2016;57(10):1610\u20136. https:\/\/doi.org\/10.1111\/epi.13509.","journal-title":"Epilepsia"},{"issue":"26","key":"2109_CR32","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1804092.","journal-title":"N Engl J Med"},{"key":"2109_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1277734","volume":"14","author":"X Zhou","year":"2024","unstructured":"Zhou X, Yang G, Zeng X, et al. Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis. Front Immunol. 2024;14:1277734. https:\/\/doi.org\/10.3389\/fimmu.2023.1277734.","journal-title":"Front Immunol"},{"issue":"1","key":"2109_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/19458924241280757","volume":"39","author":"D Gershnabel Milk","year":"2025","unstructured":"Gershnabel Milk D, Lam KK, Han JK. Postmarketing analysis of eosinophilic adverse reactions in the use of biologic therapies for type 2 inflammatory conditions. Am J Rhinol Allergy. 2025;39(1):38\u201348. https:\/\/doi.org\/10.1177\/19458924241280757.","journal-title":"Am J Rhinol Allergy"},{"issue":"7","key":"2109_CR35","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/17476348.2022.2090342","volume":"16","author":"M Caminati","year":"2022","unstructured":"Caminati M, Olivieri B, Dama A, et al. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med. 2022;16(7):713\u201321. https:\/\/doi.org\/10.1080\/17476348.2022.2090342.","journal-title":"Expert Rev Respir Med"},{"issue":"5","key":"2109_CR36","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1445-5994.1977.tb03375.x","volume":"7","author":"HL Chan","year":"1977","unstructured":"Chan HL, Ku G, Khoo OT. Allopurinol associated hypersensitivity reactions: cutaneous and renal manifestations. Aust N Z J Med. 1977;7(5):518\u201322. https:\/\/doi.org\/10.1111\/j.1445-5994.1977.tb03375.x.","journal-title":"Aust N Z J Med"},{"issue":"1","key":"2109_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-16062-w","volume":"15","author":"HT Pham","year":"2025","unstructured":"Pham HT, Tran MH, Mai Hoang TV, et al. HLA-B*58:01 genotyping prevalence and the association with allopurinol-induced severe cutaneous adverse reactions: a living systematic review and meta-analysis. Sci Rep. 2025;15(1):30742. https:\/\/doi.org\/10.1038\/s41598-025-16062-w.","journal-title":"Sci Rep"},{"issue":"14","key":"2109_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144576","volume":"12","author":"M Dagnon da Silva","year":"2023","unstructured":"Dagnon da Silva M, Domingues SM, Oluic S, et al. Renal manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review of 71 cases. J Clin Med. 2023;12(14):4576. https:\/\/doi.org\/10.3390\/jcm12144576.","journal-title":"J Clin Med"},{"issue":"6","key":"2109_CR39","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s11096-024-01778-y","volume":"46","author":"W Li","year":"2024","unstructured":"Li W, Yu Y, Li M, et al. Identification of novel signal of proton pump inhibitor-associated drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis. Int J Clin Pharm. 2024;46(6):1381\u201390. https:\/\/doi.org\/10.1007\/s11096-024-01778-y.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"2109_CR40","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/bjd.12125","volume":"168","author":"A Barbaud","year":"2013","unstructured":"Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555\u201362. https:\/\/doi.org\/10.1111\/bjd.12125.","journal-title":"Br J Dermatol"},{"issue":"10","key":"2109_CR41","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/j.cgh.2020.08.020","volume":"19","author":"EB Mougey","year":"2021","unstructured":"Mougey EB, Nguyen V, Guti\u00e9rrez-Junquera C, et al. STAT6 variants associate with relapse of eosinophilic esophagitis in patients receiving long-term proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2021;19(10):2046-2053.e2. https:\/\/doi.org\/10.1016\/j.cgh.2020.08.020.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2109_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1488483","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang D, Wu S, et al. Literature review of the clinical features of sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome (DRESS\/DIHS). Front Pharmacol. 2024;15:1488483. https:\/\/doi.org\/10.3389\/fphar.2024.1488483.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2109_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1183\/09031936.03.00031102","volume":"22","author":"JR Gordon","year":"2003","unstructured":"Gordon JR, Swystun VA, Li F, et al. Regular salbutamol use increases CXCL8 responses in asthma: relationship to the eosinophil response. Eur Respir J. 2003;22(1):118\u201326. https:\/\/doi.org\/10.1183\/09031936.03.00031102.","journal-title":"Eur Respir J"},{"issue":"1 Pt 1","key":"2109_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1067\/mai.2000.107396","volume":"106","author":"VA Swystun","year":"2000","unstructured":"Swystun VA, Gordon JR, Davis EB, et al. Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. J Allergy Clin Immunol. 2000;106(1 Pt 1):57\u201364. https:\/\/doi.org\/10.1067\/mai.2000.107396.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2109_CR45","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s10067-024-07000-8","volume":"43","author":"G Alexander","year":"2024","unstructured":"Alexander G, Moore SA, Lenert PS. Eosinophilic granulomatosis with polyangiitis and its association with montelukast: a case-based review. Clin Rheumatol. 2024;43(6):2153\u201365. https:\/\/doi.org\/10.1007\/s10067-024-07000-8.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"2109_CR46","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1053\/sarh.2002.27735","volume":"31","author":"G Jamaleddine","year":"2002","unstructured":"Jamaleddine G, Diab K, Tabbarah Z, et al. Leukotriene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum. 2002;31(4):218\u201327. https:\/\/doi.org\/10.1053\/sarh.2002.27735.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"2109_CR47","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1378\/chest.93.5.1067","volume":"93","author":"WJ Martin 2nd","year":"1988","unstructured":"Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (part I). Chest. 1988;93(5):1067\u201375. https:\/\/doi.org\/10.1378\/chest.93.5.1067.","journal-title":"Chest"},{"issue":"10","key":"2109_CR48","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1253\/circj.71.1610","volume":"71","author":"Y Yamada","year":"2007","unstructured":"Yamada Y, Shiga T, Matsuda N, et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J. 2007;71(10):1610\u20136. https:\/\/doi.org\/10.1253\/circj.71.1610.","journal-title":"Circ J"},{"issue":"4","key":"2109_CR49","doi-asserted-by":"publisher","first-page":"816","DOI":"10.5114\/ada.2021.109586","volume":"39","author":"E Minenna","year":"2022","unstructured":"Minenna E, Chaoul N, Rossi MP, et al. Sustained drug-related reaction with eosinophilia and systemic symptoms (DRESS) triggered by low molecular weight heparins in COVID-19: management and precision diagnosis. Postepy Dermatol Alergol. 2022;39(4):816\u20138. https:\/\/doi.org\/10.5114\/ada.2021.109586.","journal-title":"Postepy Dermatol Alergol"},{"issue":"3","key":"2109_CR50","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000345096","volume":"4","author":"S Ronceray","year":"2012","unstructured":"Ronceray S, Dinulescu M, Le Gall F, et al. Enoxaparin-induced DRESS syndrome. Case Rep Dermatol. 2012;4(3):233\u20137. https:\/\/doi.org\/10.1159\/000345096.","journal-title":"Case Rep Dermatol"},{"issue":"8","key":"2109_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad414","volume":"10","author":"N Okada","year":"2023","unstructured":"Okada N, Niimura T, Saisyo A, et al. Pharmacovigilance study on eosinophilic pneumonia induced by anti-MRSA agents: analysis based on the FDA adverse event reporting system. Open Forum Infect Dis. 2023;10(8):ofad414. https:\/\/doi.org\/10.1093\/ofid\/ofad414.","journal-title":"Open Forum Infect Dis"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02109-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02109-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02109-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:31:15Z","timestamp":1784035875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02109-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["2109"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02109-z","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study used publicly available de-identified data from the FAERS database. Because no patient-identifiable information was accessed, institutional ethics approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}